Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…Genetic variation near the SNCA gene associates with Parkinson’s disease motor phenotype and progression
Objective: To examine the extent to which single nucleotide polymorphisms (SNPs) are associated with motor phenotype and progression in Parkinson's disease (PD). Background: Tremor-dominant (TD)…A novel single molecule imaging approach to detect individual protein oligomers in CSF from patients with Parkinson’s disease (PD)
Objective: (1) To develop an ultra-sensitive method to visualize single amyloid oligomers and (2) to compare the oligomer load in CSF from patients with PD…The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset
Objective: The goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical, imaging and biospecimen biomarkers of PD progression to provide tools for…Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy
Objective: To assess the therapeutic efficacy of the caspase-1 inhibitor prodrug VX-765 on alpha-synuclein (α-syn) pathology and neuroprotection in a transgenic mouse model of multiple…Functional characterisation and the selective vulnerability of SNCA (A30P) patient-derived midbrain dopaminergic neurons to ER stress
Objective: To functional characterise and phenotype the genetic Parkinson's disease (PD) patient with an A30P point mutation in SNCA using midbrain dopaminergic neurons (mDANs) vs…Exosomes-injection to reproduce a mouse model of Parkinson’s disease: A preliminary report
Objective: To explore the pathogenicity of exosomes derived from Parkinson's disease (PD) patients' serum and healthy control's serum in vivo and verify the prion-like propagation…Impaired hippocampal neurogenesis associates with serotonergic axonal degeneration in transgenic rat and mouse models of Parkinson’s disease
Objective: To evaluate the impact of α-synuclein accumulation on the hippocampal serotonergic system and hippocampal plasticity in two different α-synuclein expressing rodent models. Background: Parkinson's…Characterisation of the A30P mutation in alpha-synuclein gene in patient-derived cellular model of Parkinson’s disease
Objective: In this study, we aim to generate and characterise patient-derived midbrain dopaminergic neurons (mDANs) of the A30P Parkinson's disease (PD) familial case. Our goal…Increased cellular co-localization of tau fragment 1-368 and alpha-synuclein in two mouse model of Parkinson’s disease
Objective: To examine the distribution of a novel tau pathology and its interaction with alpha-synuclein in two mouse model of Parkinson's disease (PD). Background: Cleavage…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.